Janssen Bets On Simeprevir For HCV In China; Partners With Hepatology Society
This article was originally published in PharmAsia News
It may take four to five years for next-generation oral hepatitis C therapies to take hold in China, and Johnson & Johnson subsidiary Janssen Inc. isn’t wasting any time stepping up efforts to increase disease awareness via partnerships.
You may also be interested in...
Gilead and AbbVie are seen as running neck-and-neck to bring the first all-oral combo of direct-acting antivirals to market in HCV, but Gilead’s regimen is expected to win a larger market share. Idenix is starting over in the nucleoside space, but expects to bring a uridine-based “nuc” into clinical development by mid-year.
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.